Accueil>>Signaling Pathways>> GPCR/G protein>> GPR119>>PSN632408

PSN632408

Catalog No.GC10365

PSN632408, un agoniste sélectif du GPR119 actif par voie orale, présente une puissance similaire À celle de l'OEA sur les récepteurs GPR119 recombinants de souris et humains (EC50 = 5,6 et 7,9 uM, respectivement).

Products are for research use only. Not for human use. We do not sell to patients.

PSN632408 Chemical Structure

Cas No.: 857652-30-3

Taille Prix Stock Qté
5mg
60,00 $US
Ship Within 10-14 Days
10mg
98,00 $US
Please Inquire
50mg
439,00 $US
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PSN632408 is a novel, selective and small-molecule agonist of human and mouse GPR119 with EC50 values of 5.6±0.99 μM and 7.9±0.7 μM, respectively [1].

PSN632408 has been reported to activate human and mouse GPR119 in a yeast fluorimetric assay with EC50 of 5.6±0.99 μM and 7.9±0.7 μM, respectively. In HEK-OSGPR116 cells, cAMP level was dose-dependently increased by PSN632408 with an EC50 of 1.9±0.14 μM.. In vivo, PSN632408 induced food intake reduction by using a rat feeding model and acute hypophagic effects in dose-dependence [1].

References:
[1] Overton HA1, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C.Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006 Mar;3(3):167-75

Avis

Review for PSN632408

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PSN632408

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.